July 11, 2022
Via: PharmaphorumAbbVie first bought in to the programme with a $205 million upfront payment five years ago, attracted by the potential to use checkpoint inhibitors to try to reproduce in neurology the sometimes stunning results achieved with the class in oncology. […]
July 19, 2024
July 11, 2024
July 11, 2024